Printer Friendly

Pulmatrix announces inclusion in Russell Microcap Index.

M2 PHARMA-June 24, 2016-Pulmatrix announces inclusion in Russell Microcap Index

(C)2016 M2 COMMUNICATIONS

Biopharmaceutical company Pulmatrix (NasdaqGM:PULM) reported on Friday that it has been added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of US and global equity indexes on June 24, 2016.

The company said the inclusion in the index will bring greater shareholder awareness of its progress in developing novel inhaled drugs for crucial unmet medical needs.

According to the company, the membership in the Russell Microcap Index is based on market capitalisation and means automatic inclusion in the appropriate growth and value style indexes.

In conjunction, the company is moving ahead with a pipeline of innovative inhaled drugs based on its iSPERSE technology and believes iSPERSE will enable the efficient delivery of drugs directly to the lungs with fewer side effects compared to existing products. Its first three product candidates are engineered to treat chronic obstructive pulmonary disease (COPD), fungal infections in the lungs, and idiopathic pulmonary fibrosis (IPF).

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 24, 2016
Words:179
Previous Article:Teva Pharmaceutical Industries receives encouraging opinion from EMA CHMP for CINQAERO to treat severe eosinophilic asthma.
Next Article:St. Jude Medical Granted CE Mark Approval for SyncAV CRT Software.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters